Disease severity and outcome in thymoma myasthenia gravis: A long-term observation study

European Journal of Neurology

Volumn 10, Issue 6, 2003, Pages 701-706

  Romi, F ^a   Gilhus, N E ^a   Varhaug, J E ^a   Myking, A ^a   Aarli, J A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acetylcholine receptor antibodies; Myasthenia gravis severity; Ryanodine receptor antibodies; Thymoma; Titin antibodies

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CONNECTIN; CORTICOSTEROID; MUSCLE ANTIBODY; RYANODINE RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MALE; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RESPIRATORY FAILURE; THYMECTOMY; THYMOMA; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGE OF ONSET; AUTOANTIBODIES; AZATHIOPRINE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MUSCLE PROTEINS; MYASTHENIA GRAVIS; PROTEIN KINASES; RECEPTORS, CHOLINERGIC; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; THYMECTOMY; THYMOMA; THYMUS GLAND; THYMUS NEOPLASMS; TREATMENT OUTCOME;

EID: 0346334486     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2003.00678.x     Document Type: Article

References (30)

1. Aarli JA (1999). Late-onset myasthenia gravis. A changing scene. Arch Neurol 56:25-27.
2. Baggi F, Andreetta F, Antozzi C et al. (1998). Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma. Ann N Y Acad Sci 841:538-541.
3. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW (1998). Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 841:769-772.
4. Detterbeck FC, Scott WW, Howard JF et al. (1996). One hundred concecutive thymectomies for myasthenia gravis. Ann Thorac Surg 62:242-245.
5. Evoli A, Minisci C, Di Schino C et al. (2002). Thymoma in patients with MG: characteristics and long-term outcome. Neurology 59:1844-1850.
6. Gronseth GS, Barohn RJ (2000). Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review). Neurology 55:7-15.
7. Jaretzki A III, Barohn RJ, Ernstoff RM et al. (2000). Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16-23.
8. Lefvert AK, Bergstrøm K, Matell G, Osterman PO, Pirskanen R (1978). Determination of acetylcholine receptor antibody in myasthenia gravis - clinical usefulness and pathogenic implications. J Neurol Neurosurg Psychiat 41:394-403.
9. Liu W, Tong T, Ji Z, Zhang Z (2002). Long-term prognostic analysis of thymectomized patients with myasthenia gravis. Chin Med J 115:235-237.
10. MacMahon B (1996). Cohort studies. In: MacMahon B, Trichopoulos D, eds. Epidemiology Principles and Methods. Little, Brown and Company, Boston, NY, Toronto, London, pp. 168-223.
11. Marx A, Schömig D, Shultz A et al. (1994). Distribution of molecules mediating thymocyte-stroma-interaction in human thymus, thymitis and thymic epithelial tumors. Thymus 23:83-93.
12. Müller-Hermelink HK, Marx A (1999). Pathological aspects of malignant and benign thymic disorders. Ann Med 31(Suppl. 2):5-14.
13. Müller-Hermelink HK, Marx A, Kirchner T (1993). The pathological basis of thymoma associated myasthenia gravis. Ann NY Acad Sci 681:56-65.
14. Mygland Å, Tysnes OB, Matre R, Volpe P, Aarli JA, Gilhus NE (1992). Ryanodine receptor autoantibodies in myasthenia gravis patients with thymoma. Ann Neurol 32:589-591.
15. Mygland Å, Aarli JA, Matre R, Gilhus NE (1994). Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatry 57:843-846.
16. Myking AO, Skeie GO, Varhaug JE, Andersen KS, Gilhus NE, Aarli JA (1998). The histomorphology of the thymus in late onset, non-thymoma myasthenia gravis. Eur J Neurol 5:401-405.
17. Osserman K, Genkins G (1971). Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mount Sinai J Med 38:497-537.
18. de Perrot M, Liu J, Bril V, McRae K, Bezjak A, Keshavjee SH (2002). Prognostic significance of thymomas in patients with myasthenia gravis. Ann Thorac Surg 74:1658-1662.
19. Romi F, Skeie GO, Aarli JA, Gilhus NE (2000a). Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 247:369-375.
20. Romi F, Skeie GO, Aarli JA, Gilhus NE (2000b). The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol 57:1596-1600.
21. Romi F, Gilhus NE, Varhaug JE, Myking A, Skeie GO, Aarli JA (2002a). Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. Eur J Neurol 9:55-61.
22. Romi F, Bø L, Skeke OG, Myking A, Aarli JA, Gilhus NE (2002b). Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with co-stimulatory molecules. J Neuroimmunol 128:82-89.
23. Romi F, Gilhus NE, Varhaug JE, Myking A, Skeie GO, Aarli JA (2003). Thymectomy in non-thymoma early-onset myasthenia gravis, in correlation with disease severity and muscle autoantibodies. Eur Neurol 49:210-217.
24. Scott W, Detterbeck F (1999). Transsternal thymectomy for myasthenia gravis. Semin Thorac Cardiovasc Surg 11:54-58.
25. Skeie GO, Mygland Å, Aarli JA, Gilhus NE (1995). Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity 20:99-104.
26. Skeie GO, Bartoccioni E, Evoli A, Aarli JA, Gilhus NE (1996). Ryanodine receptor antibodies are associated with severe myasthenia gravis. Eur J Neurol 3:136-140.
27. 2+ release channel (ryanodine receptor) in myasthenia gravis: epitope mapping and functional effect on calcium release from sarcoplasmic reticulum in vitro. Muscle Nerve 27:81-89.
28. Venuta F, Rendina EA, De Giacomo T et al. (1999). Thymectomy for myasthenia gravis: a 27-year experience. Eur J Cardiothorac Surg 15:621-625.
29. Voltz RD, Albrich WC, Nägele A et al. (1997). Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor. Neurology 49:1454-1457.
30. Whooley BP, Urschel JD, Antkowiak JG, Takita H (2000). A 25-year thymoma treatment review. J Exp Clin Cancer Res 19:3-5.